Drug Trial Radar · NCT05151705
A Trial of HR17031 Injection With Hepatic Insufficiency
Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 20, 2021
Primary completion
Jun 15, 2022
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.
Conditions
- Improved Glycemic Control in Patients With Type 2 Diabetes
Interventions
HR17031 injectionDrug
Treatment group A:HR17031 injection; 10U/0.024mg
HR17031 injectionDrug
Treatment group B: HR17031 injection; 10U/0.024mg
HR17031 injectionDrug
Treatment group C: HR17031 injection; 10U/0.024mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics parameters of INS068 and SHR20004: CmaxTime frame: Based on pre-dose, 2-96 hours post-dose sampling times
- Pharmacokinetics parameters of INS068 and SHR20004: AUC0-tTime frame: Based on pre-dose, 2-96 hours post-dose sampling times
- Pharmacokinetics parameters of INS068 and SHR20004: AUC0-infTime frame: Based on pre-dose, 2-96 hours post-dose sampling times
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.